Premier Research Group, the clinical-development services company based in Philadelphia, US, has reinforced its home-market presence by opening new facilities that boost testing capacity at its clinical research sites in Phoenix and Salt Lake City by 50%.

The expansion will accommodate more Phase I and more outpatient studies, with increased capability to reach and house volunteers as well as facilities for Phase II and III trials in chronic pain, migraine, dysmenorrhoea, obesity, vaccination and other therapy areas, Premier said.

The company has been in the Phoenix market since 1993 and in Salt Lake City since 1999.  

In addition to its offerings as a full-service contract research organisation, Premier Research owns and operates a network of clinical research centres with services ranging from Phase 1 proof-of-concept trials to Phase IV post-marketing studies, mainly in the fields of acute and chronic pain, rheumatology and neuroscience.

Founded in 1989, the company has 21 offices across North America and Europe and operates in more than 30 countries worldwide.